BioMarin Pharmaceutical Inc

BMRN 
(NASDAQ) 
 
$ 82,08 <%= Resources.Global.txtDown %>
Opdateret 23-04-2018
Ændring % -0,27% Fald i aktiekurs
Ændring -0,22 Fald i aktiekurs
Volume 387.843
Høj $ 83,01
Lav $ 81,63
Åben $ 82,15
ISIN
Seneste luk $ 82,30
# af aktier 176,07M
Markedsværdi 14.452M USD
I dag

Market closed
BioMarin Pharmaceutical Inc
Markedet er lukket, åbner klokken 15:30
 
Kursudvikling Seneste 1 uge 1 måned 3 mdr 6 mdr 1 år
 
  82,08 -2,8% Fald i aktiekurs 4,1% Stigning i aktiekurs -10,1% Fald i aktiekurs -4,9% Fald i aktiekurs -12,2% Fald i aktiekurs
Powered by TradingView

Nyheder om BioMarin Pharmaceutical Inc

Firmaprofil

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme and Vimizim independently. BioMarin markets Kuvan--to treat the rare metabolic disorder PKU--in the U.S., and recently reacquired international rights for Kuvan and PKU drug candidate pegvaliase from Merck KGaA. BioMarin expanded its pipeline with acquisitions in 2010 (LEAD Therapeutics and Zystor) and 2015 (Prosensa).

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. april 2018 14:14:01
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180423.5 - EUROWEB4 - 2018-04-24 14:14:01 - 2018-04-24 14:14:01 - 1 - Website: OKAY